http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 06 Aug 2026 20:03:33 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/IPOs/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html <p>Latigo Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on non-opioid pain medicines, priced its initial public offering of 19,200,000 shares of common stock at $18.00 per share, according to a press release dated Aug. 6, 2026.</p> <p>The gross proceeds from the offering are expected to total $345.6 million before underwriting discounts, commissions, and other expenses. The underwriters have a 30-day option to purchase up to an additional 2,880,000 shares at the public offering price, less underwriting discounts and commissions.</p> <p>Shares are expected to begin trading on the Nasdaq Global Select Market on Aug. 7, 2026, under the ticker symbol NASDAQ: LTGO. The http://www.streetinsider.com/Equity+Offerings/Latigo+Biotherapeutics+prices+%24345.6M+IPO+at+%2418+per+share/26886046.html Thu, 06 Aug 2026 20:03:33 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Press+Releases/Latigo+Biotherapeutics+Announces+Pricing+of+Upsized+%24345.6+Million+Initial+Public+Offering/26886045.html <p align="justify">THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Latigo. The gross proceeds to Latigo from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Latigo, are expected to be $345.6 million. In addition, the underwriters have a 30-day option to http://www.streetinsider.com/Press+Releases/Latigo+Biotherapeutics+Announces+Pricing+of+Upsized+%24345.6+Million+Initial+Public+Offering/26886045.html Thu, 06 Aug 2026 20:03:00 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Press+Releases/Latigo+Biotherapeutics+Announces+Pricing+of+Upsized+%24345.6+Million+Initial+Public+Offering/26886045.html <p align="justify">THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Latigo. The gross proceeds to Latigo from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Latigo, are expected to be $345.6 million. In addition, the underwriters have a 30-day option to http://www.streetinsider.com/Press+Releases/Latigo+Biotherapeutics+Announces+Pricing+of+Upsized+%24345.6+Million+Initial+Public+Offering/26886045.html Thu, 06 Aug 2026 20:03:00 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686 http://www.streetinsider.com/Press+Releases/Latigo+Biotherapeutics+Announces+Pricing+of+Upsized+%24345.6+Million+Initial+Public+Offering/26886045.html <p align="justify">THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Latigo. The gross proceeds to Latigo from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Latigo, are expected to be $345.6 million. In addition, the underwriters have a 30-day option to http://www.streetinsider.com/Press+Releases/Latigo+Biotherapeutics+Announces+Pricing+of+Upsized+%24345.6+Million+Initial+Public+Offering/26886045.html Thu, 06 Aug 2026 20:03:00 -0400 A.10371245 A.14185667 A.15776824 A.36817542 A.50216971 LTGO O.22066148 O.25213119 O.47721603 O.51342512 O.51342686